Eyenovia to Report First Quarter 2021 Results on Wednesday, May 12

Rhea-AI Summary

Eyenovia, Inc. (NASDAQ: EYEN) will announce its Q1 2021 financial results on May 12, 2021, after market close. A conference call will follow at 4:30 PM ET, featuring CEO Dr. Sean Ianchulev, COO Michael Rowe, and CFO John Gandolfo. Participants can join by calling 877-407-9039 or 201-689-8470, using conference code 13718776. A live webcast is accessible on Eyenovia's investor relations page and will be archived for one year.

Eyenovia focuses on developing microdose array print (MAP) therapeutics for eye conditions.

Company to host an investor conference call and webcast at 4:30pm ET on that day

NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced that the Company will release financial results for the first quarter ended March 31, 2021 on Wednesday, May 12, 2021, after market close. Following the release, Eyenovia’s Chief Executive Officer and Chief Medical Officer, Dr. Sean Ianchulev, Chief Operating Officer, Michael Rowe, and Chief Financial Officer, John Gandolfo, will host a conference call to review the financial and operating results.

The conference call is scheduled to begin at 4:30 pm ET. Participants should dial 877-407-9039 (domestic) or 201-689-8470 (international) with the conference code 13718776. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.eyenovia.com.

After the live webcast, the event will be archived on Eyenovia’s website for one year.

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. For more Information, visit www.eyenovia.com.

Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com

Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363

Eyenovia Media Contact:
Diana Soltesz
Pazanga Health Communications
dsoltesz@pazangahealth.com
(818) 618-5634

FAQ

When will Eyenovia release its Q1 2021 financial results?

Eyenovia will release its Q1 2021 financial results on May 12, 2021, after market close.

What time is the Eyenovia investor conference call?

The investor conference call for Eyenovia is scheduled for 4:30 PM ET on May 12, 2021.

How can I access the Eyenovia conference call?

You can access the Eyenovia conference call by dialing 877-407-9039 (domestic) or 201-689-8470 (international) with the conference code 13718776.

Will the Eyenovia conference call be available as a webcast?

Yes, a live webcast of the Eyenovia conference call will be available on the investor relations page of their website.

What is the focus of Eyenovia's development efforts?

Eyenovia is focused on developing microdose array print (MAP) therapeutics for conditions such as presbyopia, myopia progression, and mydriasis.